Columbia Care (NEO:CCHW,OTC Pink:COLXF) announced the opening of 20 medical cannabis dispensaries in Florida last Thursday (July 5).

The company expects to have all 20 dispensaries either open or under development in the state by the end of 2019.

The first of the company’s new dispensaries in Florida will be its 4,000 square foot Gainesville location set to open on July 16. Columbia Care CEO Nicholas Vita said in a press release that the rapid growth of cannabis providers and patients in Florida makes the state a prime location.

“Since acquiring our Florida license in 2018, Columbia Care has been quietly assembling its portfolio of dispensaries and building the requisite infrastructure to support the pace of growth that has made the State such a strategic market,” said Vita.

The Gainesville facility will offer Columbia Care’s tinctures, capsules and vaporization devices for medical use. The company also intends to make its in-house medical cannabis brands available in tablet and topical form by the end of the year.

Analyst Matt Bottomley, director of equity research at Canaccord Genuity, has spoken highly of Florida as one of the growing cannabis markets in the US.

Haywood Securities analyst Neal Gilmer shares that sentiment. In a 2018 report on the cannabis market in the US, Gilmer wrote that, while Florida is in the early stages of cannabis adoption, “we believe (it) will continue to support strong growth metrics as the medical program continues to evolve.”

Cannabis legalization has faced obstacles in the state. Despite a majority of Floridians — over 70 percent — voting for a constitutional amendment that would allow the use of cannabis for medical conditions in 2016, then-Governor Rick Scott signed a ban on smoking medical cannabis that was enacted in 2017.

Earlier this year, Florida’s current governor, Ron DeSantis, signed legislation to overturn the ban.

While recreational use is still illegal in the state, the recent legalization of smoking medical cannabis in Florida has made it an attractive market for multi-state operators (MSOs) like Columbia Care.

Other MSOs in Florida have also taken note of the state’s quickly growing medical cannabis market.

Cresco Labs (CSE:CL,OTCQX:CRLBF), a US cannabis company, made its entrance into Florida’s market with its agreement to acquire the ownership interests or assets of VidaCann, one of Florida’s largest providers of medical cannabis, earlier this year. Cresco Labs opened up its 12th VidaCann-branded medical marijuana dispensary in Florida last month.

In its 2018 year-end financial report, released earlier this year, Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) credited a boost in its revenue to its expansions in Florida and New York, as well as acquisitions in Arizona and Massachusetts.

Another MSO, Trulieve Cannabis (CSE:TRUL,OTC Pink:TCNNF), saw a jump in its share price in March when it began to sell smokable medical cannabis products in Florida, becoming the first company in the state to sell “whole-flower smokable cannabis,” according to a press release.

In a recent update from the Florida Office of Medical Marijuana Use, it was reported that there are currently 142 dispensary locations across Florida. Trulieve has the largest number of dispensaries with 30 locations, while Curaleaf and VidCann have 25 and 12 locations, respectively.

According to Statista, medical cannabis sales in Florida will be valued at about US$2.5 billion by 2025.

Shares of Columbia Care opened at C$5.87 Wednesday (July 10) and closed at C$5.61. Since its announcement on July 5, the company’s share price has dipped 16 percent from C$6.69.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact, or

Keep reading... Show less